TABLE 1

Summary of Patient Scans and Treatment Regimens

Patient no.Age (y)Prostate-specific antigen at baselineGleason scoreKPSNo. of PET scansSite of diseaseTherapeutic regimen
165885.059803BoneDocetaxel (Sanofi-Aventis)
26896.6210803Bone, lymph node, prostatic mass, soft tissueDocetaxel (Sanofi-Aventis)
37510.445901Bone17AAG (AG Scientific), docetaxel (Sanofi-Aventis)
47324.907903Lymph nodeAbiraterone (Cougar Biotechnology)
5597.529903Bone, lymph nodeAbiraterone (Cougar Biotechnology)
64927.047903Lymph nodeMDV3100 (Medivation, Inc.)
75396.459903Bone, lymph node17AAG (AG Scientific), docetaxel (Sanofi-Aventis)
87447.227802BoneDocetaxel (Sanofi-Aventis)
9700.497902Bone17AAG (AG Scientific), docetaxel (Sanofi-Aventis)
10595.289803LiverDocetaxel (Sanofi-Aventis)
117610.426902BonePalliative radiotherapy to sacrum
126717.5110801Bone, lymph node, liver5-Fluorouracil (Pharmacia and Upjohn), oxaliplatin (Sanofi-Aventis)
13791.527801*Bicalutamide (AstraZeneca)
  • * Reading for patient 13 had confidence of metastases of equivocal; therefore, sites of disease were not identified.